重度憂鬱症：全球市場展望、流行病學、競爭格局和市場預測報告（32個主要市場），2025-2035年

市場概覽

• 德國 MDD 市場預計將從 2025 年的約 2.4 億美元成長到 2035 年的約 5.65 億美元，複合年成長率約為 8-9%。
• 義大利確診病例數量成長非常緩慢（年均複合成長率約為0.4%），顯示：
• 該疾病的盛行率保持穩定。
• 市場成長更多是由治療方法的創新驅動，而不是由患者數量的增加所驅動。

重度憂鬱症概述

重度憂鬱症（MDD）是一種常見且嚴重的精神疾病，其特徵是持續性情緒低落、快感缺失（興趣或愉悅感喪失）以及功能障礙，且持續至少兩週。它影響所有年齡層的人群，是由遺傳、神經生物學、心理學和環境因素的複雜相互作用引起的。

臨床上，重度憂鬱症表現為多種症狀，包括疲勞、睡眠障礙、食慾改變、注意力難以集中、內疚和無價值感，嚴重時可能伴隨自殺意念或自殺行為。

此疾病的診斷主要依據臨床表現，並參考DSM-5等標準化診斷標準，在仔細排除其他精神和生理疾病後進行。此疾病具有高度異質性，其嚴重程度、復發率和治療反應均有差異。

治療方案採用多管齊下的方法。具體而言，包括以下內容：

• 心理治療（主要是認知行為治療）
• 藥物治療（SSRIs、SNRIs 和其他抗憂鬱症）
• 生活方式改善和支持性干預

儘管存在多種治療選擇，但相當一部分患者表現出治療抗藥性或僅獲得不完全療效，這凸顯出仍存在大量未滿足的需求。

主要亮點

• 法國被診斷出患有重度憂鬱症(MDD) 的人數眾多且相對穩定，預計將從 2025 年的約 443 萬人增加到 2035 年的約 459 萬人。然而，成長率較低（年複合成長率約為 0.4%），顯示成長趨勢趨於平緩。
• 相當一部分患者（約 20-30%）被歸類為患有難治性憂鬱症(TRD)，這推動了對先進治療方法的需求。
• 目前的治療領域仍以學名藥主導。
• SSRI 和 SNRI 被用作第一線治療藥物（約佔 60-70% 的市場佔有率）。
• 輔助性治療（抗精神病藥物、情緒穩定劑）的廣泛應用

市場定義：

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化在 32 個市場（北美、歐洲、中東、亞太、非洲和南美/拉丁美洲）的藥物開發和生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准和順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

目標國家：30個國家

• 北美洲（美國、加拿大）
• 歐洲（奧地利、比利時、捷克、丹麥、芬蘭、法國、德國、希臘、義大利、荷蘭、挪威、波蘭、葡萄牙、俄羅斯、西班牙、瑞典、瑞士、英國）
• 中東（沙烏地阿拉伯、阿拉伯聯合大公國、科威特、土耳其）
• 亞太地區（澳洲、中國、香港、印度、印尼、日本、馬來西亞、紐西蘭、菲律賓、新加坡、韓國、台灣、泰國、越南）
• 非洲（埃及、奈及利亞、南非、摩洛哥）
• 南美洲/拉丁美洲（阿根廷、巴西、智利、哥倫比亞、墨西哥、秘魯）

大公司

• Biohaven Therapeutics Ltd.
• Cybin IRL Limited
• Xenon Pharmaceuticals Inc.
• Neurocrine Biosciences
• Biogen
• Eli Lilly and Company
• AbbVie
• Axsome Therapeutics, Inc.
• Otsuka Pharmaceutical Development &Commercialization, Inc.
• Neumora Therapeutics, Inc.
• Engrail Therapeutics INC
• Janssen-Cilag Ltd.
• Autobahn Therapeutics, Inc.
• Navitor Pharmaceuticals, Inc.
• Takeda
• Syndeio Biosciences, Inc
• Suven Life Sciences Limited
• Definium Therapeutics US, Inc.
• Boehringer Ingelheim
• Relmada Therapeutics, Inc.
• Sirtsei Pharmaceuticals, Inc.
• Intra-Cellular Therapies, Inc.
• COMPASS Pathways
• Beijing Greatway Pharmaceutical Technology Co.,Ltd.
• Bausch Health Americas, Inc.
• Alto Neuroscience
• Gilgamesh Pharmaceuticals
• BioLite, Inc.
• Luye Pharma Group Ltd.
• Vigonvita Life Sciences
• Draig Therapeutics Ltd
• Supernus Pharmaceuticals, Inc.
• Ono Pharmaceutical Co. Ltd
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• Vanda Pharmaceuticals
• Seaport Therapeutics
• Jiangsu Nhwa Pharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sichuan Purity Pharmaceutical Technology Co., Ltd.
• ACADIA Pharmaceuticals Inc.
• Corium Innovations, Inc.

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物類別分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要治療方法概述及KOL洞察
• 新興治療方法
• 重點
• 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
• 值得關注的早期管道

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求及其未來透過新興治療方法實現的可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Global Major Depressive Disorder Market Outlook

Thelansis's "Global Major Depressive Disorder Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) - 2025 To 2035" covers disease overview, epidemiology, kidney biopsy cases, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Major Depressive Disorder treatment modalities options for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Major Depressive Disorder Overview

Major Depressive Disorder (MDD) is a common and serious psychiatric condition characterized by persistent low mood, anhedonia (loss of interest or pleasure), and functional impairment lasting at least two weeks. It affects individuals across all age groups and is driven by a complex interplay of genetic, neurobiological, psychological, and environmental factors.

Clinically, MDD presents with a broad spectrum of symptoms, including fatigue, sleep disturbances, appetite changes, impaired concentration, and feelings of guilt or worthlessness, with severe cases associated with suicidal ideation or behavior.

Diagnosis is clinical and based on standardized criteria such as DSM-5, with careful exclusion of other psychiatric or medical conditions. The disorder is highly heterogeneous, with variability in severity, recurrence, and treatment response.

Management is multimodal and includes:

• Psychotherapy (primarily cognitive behavioral therapy)
• Pharmacotherapy (SSRIs, SNRIs, and other antidepressants)
• Lifestyle and supportive interventions

Despite the availability of multiple treatment options, a significant proportion of patients experience treatment resistance or incomplete response, highlighting substantial unmet need.

Key Highlights

• The diagnosed MDD population in France is large and relatively stable, increasing from ~4.43 million in 2025 to ~4.59 million by 2035, reflecting a low growth rate (~0.4% CAGR).
• A considerable proportion of patients fall into the treatment-resistant depression (TRD) category (~20-30%), driving demand for advanced therapies.
• The treatment landscape remains highly generic-driven, with:
• SSRIs and SNRIs as first-line therapies (~60-70% share)
• Widespread use of adjunct therapies (antipsychotics, mood stabilizers)

Market Overview

• The MDD market in Germany is projected to grow from ~$240M in 2025 to ~$565M by 2035, reflecting a strong CAGR of ~8-9%.
• The diagnosed population in Italy shows minimal growth (~0.4% CAGR), indicating:
• Stable disease prevalence
• Market growth driven more by treatment innovation than patient expansion

Market Definition:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

30 countries covered:

• North America (United States, Canada)
• Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
• Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
• Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
• Africa (Egypt, Nigeria, South Africa, Morocco)
• South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Companies Mentioned

• Biohaven Therapeutics Ltd.
• Cybin IRL Limited
• Xenon Pharmaceuticals Inc.
• Neurocrine Biosciences
• Biogen
• Eli Lilly and Company
• AbbVie
• Axsome Therapeutics, Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Neumora Therapeutics, Inc.
• Engrail Therapeutics INC
• Janssen-Cilag Ltd.
• Autobahn Therapeutics, Inc.
• Navitor Pharmaceuticals, Inc.
• Takeda
• Syndeio Biosciences, Inc
• Suven Life Sciences Limited
• Definium Therapeutics US, Inc.
• Boehringer Ingelheim
• Relmada Therapeutics, Inc.
• Sirtsei Pharmaceuticals, Inc.
• Intra-Cellular Therapies, Inc.
• COMPASS Pathways
• Beijing Greatway Pharmaceutical Technology Co.,Ltd.
• Bausch Health Americas, Inc.
• Alto Neuroscience
• Gilgamesh Pharmaceuticals
• BioLite, Inc.
• Luye Pharma Group Ltd.
• Vigonvita Life Sciences
• Draig Therapeutics Ltd
• Supernus Pharmaceuticals, Inc.
• Ono Pharmaceutical Co. Ltd
• CSPC Ouyi Pharmaceutical Co., Ltd.
• Zhejiang Huahai Pharmaceutical Co., Ltd.
• Chengdu Kanghong Pharmaceutical Group Co., Ltd.
• Vanda Pharmaceuticals
• Seaport Therapeutics
• Jiangsu Nhwa Pharmaceutical Co., Ltd.
• CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
• Sichuan Purity Pharmaceutical Technology Co., Ltd.
• ACADIA Pharmaceuticals Inc.
• Corium Innovations, Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
• Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)